Your browser doesn't support javascript.
loading
Elevation of brain glucose and polyol-pathway intermediates with accompanying brain-copper deficiency in patients with Alzheimer's disease: metabolic basis for dementia.
Xu, Jingshu; Begley, Paul; Church, Stephanie J; Patassini, Stefano; McHarg, Selina; Kureishy, Nina; Hollywood, Katherine A; Waldvogel, Henry J; Liu, Hong; Zhang, Shaoping; Lin, Wanchang; Herholz, Karl; Turner, Clinton; Synek, Beth J; Curtis, Maurice A; Rivers-Auty, Jack; Lawrence, Catherine B; Kellett, Katherine A B; Hooper, Nigel M; Vardy, Emma R L C; Wu, Donghai; Unwin, Richard D; Faull, Richard L M; Dowsey, Andrew W; Cooper, Garth J S.
Affiliation
  • Xu J; School of Biological Sciences, and Maurice Wilkins Centre for Molecular Biodiscovery, Faculty of Science, University of Auckland, New Zealand.
  • Begley P; Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, New Zealand.
  • Church SJ; Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, and Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, United Kingdom.
  • Patassini S; Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, and Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, United Kingdom.
  • McHarg S; Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, and Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, United Kingdom.
  • Kureishy N; School of Biological Sciences, and Maurice Wilkins Centre for Molecular Biodiscovery, Faculty of Science, University of Auckland, New Zealand.
  • Hollywood KA; Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, New Zealand.
  • Waldvogel HJ; Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, and Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, United Kingdom.
  • Liu H; Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, and Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, United Kingdom.
  • Zhang S; Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, and Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, United Kingdom.
  • Lin W; Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, and Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, United Kingdom.
  • Herholz K; Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, New Zealand.
  • Turner C; School of Biological Sciences, and Maurice Wilkins Centre for Molecular Biodiscovery, Faculty of Science, University of Auckland, New Zealand.
  • Synek BJ; School of Biological Sciences, and Maurice Wilkins Centre for Molecular Biodiscovery, Faculty of Science, University of Auckland, New Zealand.
  • Curtis MA; Centre for Advanced Discovery and Experimental Therapeutics (CADET), Central Manchester University Hospitals NHS Foundation Trust, and Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, United Kingdom.
  • Rivers-Auty J; Institute of Brain, Behaviour and Mental Health, Faculty of Medical and Human Sciences, University of Manchester, United Kingdom.
  • Lawrence CB; Anatomical Pathology, LabPLUS, Auckland City Hospital, Auckland, New Zealand.
  • Kellett KA; Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, New Zealand.
  • Hooper NM; Anatomical Pathology, LabPLUS, Auckland City Hospital, Auckland, New Zealand.
  • Vardy ER; Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, New Zealand.
  • Wu D; Institute of Brain, Behaviour and Mental Health, Faculty of Medical and Human Sciences, University of Manchester, United Kingdom.
  • Unwin RD; Institute of Brain, Behaviour and Mental Health, Faculty of Medical and Human Sciences, University of Manchester, United Kingdom.
  • Faull RL; Institute of Brain, Behaviour and Mental Health, Faculty of Medical and Human Sciences, University of Manchester, United Kingdom.
  • Dowsey AW; Institute of Brain, Behaviour and Mental Health, Faculty of Medical and Human Sciences, University of Manchester, United Kingdom.
  • Cooper GJ; Salford Royal NHS Foundation Trust, Salford, United Kingdom.
Sci Rep ; 6: 27524, 2016 06 09.
Article in En | MEDLINE | ID: mdl-27276998
Impairment of brain-glucose uptake and brain-copper regulation occurs in Alzheimer's disease (AD). Here we sought to further elucidate the processes that cause neurodegeneration in AD by measuring levels of metabolites and metals in brain regions that undergo different degrees of damage. We employed mass spectrometry (MS) to measure metabolites and metals in seven post-mortem brain regions of nine AD patients and nine controls, and plasma-glucose and plasma-copper levels in an ante-mortem case-control study. Glucose, sorbitol and fructose were markedly elevated in all AD brain regions, whereas copper was correspondingly deficient throughout (all P < 0.0001). In the ante-mortem case-control study, by contrast, plasma-glucose and plasma-copper levels did not differ between patients and controls. There were pervasive defects in regulation of glucose and copper in AD brain but no evidence for corresponding systemic abnormalities in plasma. Elevation of brain glucose and deficient brain copper potentially contribute to the pathogenesis of neurodegeneration in AD.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polymers / Blood Glucose / Brain / Copper / Dementia / Alzheimer Disease Type of study: Observational_studies Limits: Aged / Animals / Female / Humans / Male / Middle aged Language: En Journal: Sci Rep Year: 2016 Document type: Article Affiliation country: New Zealand Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Polymers / Blood Glucose / Brain / Copper / Dementia / Alzheimer Disease Type of study: Observational_studies Limits: Aged / Animals / Female / Humans / Male / Middle aged Language: En Journal: Sci Rep Year: 2016 Document type: Article Affiliation country: New Zealand Country of publication: United kingdom